drugset / Trial / NCT05909904
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2023-08-02
- Primary completion
- 2025-06-17
- Completion
- 2026-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alcestobart | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Surzebiclimab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |